NCT04711135 2026-02-12NETTER-PAdvanced Accelerator ApplicationsPhase 2 Active not recruiting11 enrolled 14 charts 1 FDA
NCT05249114 2025-03-10Study of Cabozantinib With Lu-177 in Patients With Somatostatin Receptor 2 Positive Neuroendocrine TumorsProvidence Health & ServicesPhase 1 Active not recruiting6 enrolled